^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK3 inhibitor

    Related drugs:
    3d
    Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. (PubMed, Front Immunol)
    This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide • tofacitinib
    7d
    Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus (clinicaltrials.gov)
    P4, N=60, Recruiting, All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tofacitinib
    11d
    ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Pfizer | Trial completion date: Aug 2026 --> Mar 2026 | Trial primary completion date: Aug 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    11d
    B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    15d
    A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice. (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Mar 2030 | Trial primary completion date: Sep 2030 --> Mar 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    16d
    KRXeljanzJIA: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (clinicaltrials.gov)
    P=N/A, N=375, Recruiting, Pfizer | Trial completion date: Jan 2027 --> Oct 2026 | Trial primary completion date: Jan 2027 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    18d
    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    18d
    TOFAST: Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P=N/A, N=280, Recruiting, Pfizer | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    21d
    A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    23d
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    25d
    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    Litfulo (ritlecitinib)
    25d
    Efficacy of Tofacitinib in Refractory Axial Spondylarthritis: A Dose-Escalation Study. (PubMed, Cureus)
    Conclusions In patients not meeting 12-week targets on 10 mg, escalation to 15 mg yielded additional clinically meaningful improvement with a safety profile generally comparable to 10 mg. Selective escalation may be a feasible treat-to-target strategy where alternatives are limited.
    Journal
    |
    CRP (C-reactive protein)
    |
    tofacitinib